Abstract
Background
Capecitabine (XELODA®) is a chemotherapeutic agent used widely in the treatment of adjuvant/metastatic colon cancer and metastatic breast cancer. It is usually well tolerated; however, one of the major side effects, hand-foot syndrome (HFS), can be quite disabling. Hyperpigmentation is currently not part of the grading system of HFS, but may be a marker of developing toxicity.
Case Report
Here, we describe three patients treated with adjuvant capecitabine for colon cancer (a 49-year-old East Indian man, a 58-year-old Asian woman, and a 54-year-old Aboriginal man) who developed moderate to severe HFS requiring delay and dose reduction. In every case, toxic side effects were preceded by hyperpigmented macules on the hands and feet.
Conclusion
Hyperpigmentation of the hands and feet is a rare side effect with capecitabine chemotherapy and appeared to predict impending grade 2 HFS in our patients. Clinicians and health care workers in oncology should be aware of this potential side effect; however, further investigation is required to determine whether or not palmar–plantar hyperpigmentation should be included in the spectrum of HFS. Hyperpigmentation may also be more common in the non-Caucasian populations but more research is required to determine the ethnic distribution of this finding.
References
XELODA® Product Monograph, December 7, 2005.
Guan Z, Yu B and Wei Y. Capecitabine: a highly effective and safe first-line chemotherapy in Chinese patients with metastatic colorectal carcinoma (MCRC). Proc Am Soc Clin Oncol 2003; 22: Abstract 1277.
Narasimhan P, Narasimhan S, Hitti IF, Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis. 2004;73:101–6.
Pui JC, Meehan S, Moskovits T. Capecitabine induced cutaneous hyperpigmentation: a case report. J Drugs Dermatol. 2002;1(2):202–5.
Lee SD, Kim HJ, Hwang SJ, Kim YJ, Nam SH, Kim BS. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med. 2007;22(2):109–12.
Vazquez-Bayo C, Rodriguez-Bujaldon AL, Jimenez-Puya R, Galan-Gutierrez M, Moreno-Gimenez JC. Capecitabine induced hyperpigmentation. Actas Dermosifiliogr. 2007;98(7):491–3. doi:10.1016/S0001-7310(07)70114-X.
LoRusso PM. Capecitabine and PPE syndrome: a case report. Breast J. 2003;9(1):64–5. doi:10.1046/j.1524-4741.2003.09119.x.
Do JE, Kim YC. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? Clin Exp Dermatol. 2007;32:519–21.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vickers, M.M., Easaw, J.C. Palmar–Plantar Hyperpigmentation with Capecitabine in Adjuvant Colon Cancer. J Gastrointest Canc 39, 141–143 (2008). https://doi.org/10.1007/s12029-009-9068-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-009-9068-9